{"id":46992,"date":"2024-05-01T09:13:54","date_gmt":"2024-05-01T08:13:54","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=46992"},"modified":"2024-09-13T13:39:14","modified_gmt":"2024-09-13T12:39:14","slug":"a-leading-clinical-research-organisation-academic-advantage","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/a-leading-clinical-research-organisation-academic-advantage\/46992\/","title":{"rendered":"A leading clinical research organisation with an academic advantage"},"content":{"rendered":"
The Montreal Health Innovations Coordinating Center<\/a> (MHICC) is a full-service academic clinical research organisation (CRO) servicing the academic community and the pharmaceutical, biotechnology, nutritional and medical device industries.<\/p>\n The MHICC\u2019s flexible, dynamic and fully integrated \u2018a la carte<\/em>\u2019 services will support your Phase I to IV clinical projects, from protocol conception, data management, and biostatistics<\/a> to delivery of clinical study reports.<\/p>\n Founded in 2001 to accompany growing clinical research activities in cardiology at the globally recognised Montreal Heart Institute (MHI), the MHICC scope has since expanded across multiple therapeutic areas.<\/p>\n There are pros and cons to either one. The academic clinical research organisation will harness scientific and medical expertise at lower fees, often with tools and systems that may not fully meet the regulatory requirements and\/or the sponsor\u2019s expectations.<\/p>\n On the other hand, the private CRO will propose advanced platforms that meet the regulatory requirements but with a hefty price tag. Luckily, you no longer have to choose!<\/p>\n The MHICC represents the best of both worlds. Offering state-of-the-art digital platforms and tools (CTMS, eTMF, eCRF, eQMS, safety database, etc.), this academic CRO distinguishes itself through its ability to conduct hybrid or decentralised clinical trials<\/a> while remaining affordable. Our new MeTRO platform eases patient involvement throughout the clinical evaluation process, thus allowing patients to participate in studies from the comfort of their homes.<\/p>\n With nearly 25 years of experience conducting clinical trials with globally renowned investigators, the MHICC has established itself as a reliable partner to drive your projects forward.<\/p>\n Being an academic institution, the potential for joint submission of grant proposals for projects with the greatest potential to advance health-related fundamental or health outcomes becomes a clear advantage. With its commitment to helping and supporting researchers and start-ups to carry their innovations to the finish line, the MHICC is your partner of choice.<\/p>\n Numerous discoveries made in academic laboratories end up shelved because of a lack of strategic development. The chain of innovation that brings lab discovery to the market is too often fragmented or incomplete. The MHICC fills the gap, playing a key role in the strategic path and navigating through all clinical trial phases that lead to commercialisation.<\/p>\n Whether you are an investigator or a pharmaceutical\/MedTech firm, the tailored-fee approach based on the range of technology can accommodate all your research needs. The MHICC\u2019s unique positioning further distinguishes itself by its access to MHI-integrated state-of-the-art capabilities in pharmacogenomics, imaging biomarkers, biobank and core laboratories.<\/p>\nAcademic or private CRO?<\/h3>\n
The academic advantage<\/h3>\n
Why partner with a Canadian CRO?<\/h3>\n